Tirzepatide vs. Semaglutide:
Clinical Differences That
Affect Patient Selection

In clinical practice, the distinction between Semaglutide and Tirzepatide is often framed as a simple efficacy comparison — "Tirzepatide produces greater weight loss." That framing is accurate but incomplete. The mechanism differences between these two compounds create meaningful distinctions in patient candidacy, side effect profile, and clinical expectations that should inform your prescribing decisions beyond just the average weight loss data.

This article is written for prescribing physicians. It assumes familiarity with GLP-1 receptor agonism and focuses on the mechanistic and clinical differences relevant to patient selection in a compounded peptide program.

The mechanism difference: why it matters clinically

Semaglutide is a selective GLP-1 receptor agonist. Its primary mechanism is stimulation of the glucagon-like peptide-1 receptor, which produces insulin secretion in a glucose-dependent manner, slows gastric emptying, reduces glucagon secretion, and suppresses appetite centrally via hypothalamic pathways.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. This dual agonism is not simply additive. GIP and GLP-1 receptors have distinct but complementary mechanisms that, in combination, produce metabolic effects that exceed what either pathway achieves alone.

Weight loss outcomes: what the trial data shows

The SURMOUNT-1 trial of Tirzepatide (15mg) produced mean weight loss of approximately 20.9% of body weight at 72 weeks. The STEP-1 trial of Semaglutide (2.4mg) produced mean weight loss of approximately 14.9% at 68 weeks. Both trials enrolled patients without diabetes; both used weekly subcutaneous injection.

The superiority of Tirzepatide in head-to-head comparison (SURMOUNT-5) is now established. At the highest doses, a meaningful proportion of Tirzepatide patients achieve weight loss exceeding 25% — a threshold historically associated with bariatric surgery outcomes.

Patient selection: when Semaglutide is the right starting point

Despite Tirzepatide's superior efficacy data, Semaglutide remains the appropriate first-line choice for a meaningful subset of patients. Clinical scenarios where Semaglutide is preferable include:

• Patients with Type 2 diabetes seeking glycemic control as the primary outcome — Semaglutide has a more established evidence base for HbA1c reduction in the T2D population, and its cardiovascular outcomes data (SUSTAIN-6, SELECT) is more extensive
• Patients who are GIP-sensitive or have had adverse reactions to GIP agonism — a minority of patients respond poorly to the GIP component; identifying this requires trial of one compound first
• Cost-sensitive patients where efficacy differential does not justify the price difference — at compounded pricing, the difference is less significant than at brand-name pricing, but remains a factor
• Patients with moderate weight loss goals (10–15% body weight) — Semaglutide's ceiling is adequate for this population, and the side effect profile may be better tolerated at lower doses
• New prescribers building comfort with the compound class — Semaglutide's longer clinical history, more established titration protocols, and more extensive post-market safety data make it an appropriate starting point

Patient selection: when Tirzepatide is the stronger choice

• Patients with significant obesity (BMI ≥ 35) where maximal weight loss is the clinical goal — the efficacy differential is most pronounced at this end of the weight spectrum
• Patients who have plateaued on Semaglutide — dual agonism provides a mechanistically distinct approach for non-responders or partial responders to GLP-1 monotherapy
• Patients with metabolic syndrome or significant insulin resistance — GIP co-agonism may provide additional benefit in this population through adipose tissue-mediated effects
• Patients who experienced intolerable nausea on Semaglutide — paradoxically, some patients tolerate Tirzepatide better despite its greater efficacy, potentially due to GIP's modulating effect on GLP-1-driven nausea
• Patients with cardiovascular risk factors — emerging data on Tirzepatide's cardiovascular effects is encouraging, though the evidence base is less mature than Semaglutide's

Side effect profiles: practical differences

Both compounds share a class-effect GI side effect profile: nausea, vomiting, diarrhea, and constipation are the most commonly reported adverse events, typically most prominent during dose titration and diminishing with continued use.

The key practical difference is tolerability at equivalent efficacy levels. Several analyses suggest that Tirzepatide's discontinuation rate due to adverse events is comparable to or lower than Semaglutide despite producing greater weight loss — consistent with the hypothesis that GIP co-agonism partially offsets GLP-1-driven nausea.

Compounded vs. branded: what changes and what doesn't

The clinical considerations above apply to both compounded and branded formulations. The compound is the same molecule. What differs in the compounded context:

• Dosing flexibility — compounded formulations allow dose titration with more granularity than the fixed-dose branded pens, which can be clinically useful for patients who need intermediate dose steps
• Administration format — compounded peptides require reconstitution and syringe-based administration, which requires patient training and comfort with self-injection technique
• Quality verification — the physician takes on greater responsibility for supplier quality in the compounded context, making independent COA verification and USP-797 certified manufacturing a baseline requirement rather than an optional preference

A practical decision framework

For most practices building a peptide program, a practical approach is to establish Semaglutide as the default starting compound for new patients and reserve Tirzepatide for patients with significant obesity, Semaglutide non-response, or specific clinical characteristics that favor dual agonism. This approach builds prescriber comfort with the compound class while making the efficacy upgrade available when clinically indicated.

Both compounds are available through the Majestic physician program, compounded at a USP-797 certified facility with independent third-party COA verification on every lot.